ABSTRACT
References .....................................................................................................................................465 15.3 Polyamines .......................................................................................................................... 469
15.3.1 Overview ............................................................................................................. 469 15.3.1.1 Life Support ...................................................................................... 469 15.3.1.2 Clinical Effects ................................................................................. 469 15.3.1.3 Laboratory ........................................................................................ 470 15.3.1.4 Treatment Overview ....................................................................... 470 15.3.1.5 Range of Toxicity ............................................................................. 471
15.3.2 Substances Included Therapeutic/Toxic Class .............................................. 471 15.3.2.1 SpeciŽc Substances .......................................................................... 471 15.3.2.2 Description ....................................................................................... 472
15.3.3 Clinical Effects Summary ................................................................................. 472 15.3.3.1 HEENT .............................................................................................. 472 15.3.3.2 Cardiovascular ................................................................................. 473 15.3.3.3 Respiratory ....................................................................................... 473 15.3.3.4 Neurologic ........................................................................................ 474 15.3.3.5 Hepatic .............................................................................................. 474 15.3.3.6 Hematologic ..................................................................................... 475 15.3.3.7 Dermatologic .................................................................................... 475 15.3.3.8 Endocrine .......................................................................................... 476 15.3.3.9 Carcinogenicity ................................................................................ 476 15.3.3.10 Immunologic .................................................................................... 476
15.3.4 Laboratory ...........................................................................................................477 15.3.4.1 Methods ............................................................................................477 15.3.4.2 Monitoring Parameters/Levels .....................................................477
